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Criteria for acute myocardial infarction
The term acute myocardial infarction (MI) should be used when there is evidence of myocardial necrosis in a clinical setting consistent with acute myocardial
ischemia. Under these conditions any one of the following criteria meets the diagnosis for MI:
● Detection of a rise and/or fall of cardiac biomarker values [preferably cardiac troponin (cTn)] with at least one value above the 99th percentile upper reference
limit (URL) and with at least one of the following:
y Symptoms of ischemia.
y New or presumed new significant ST-segment–T wave (ST–T) changes or new left bundle branch block (LBBB).
y Development of pathological Q waves in the ECG.
y Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
y Identification of an intracoronary thrombus by angiography or autopsy.
● Cardiac death with symptoms suggestive of myocardial ischemia and presumed new ischemic ECG changes or new LBBB, but death occurred before cardiac
biomarkers were obtained, or before cardiac biomarker values would be increased.
● Percutaneous coronary intervention (PCI) related MI is arbitrarily defined by elevation of cTn values (5  99th percentile URL) in patients with normal baseline
values (99th percentile URL) or a rise of cTn values 20% if the baseline values are elevated and are stable or falling. In addition, either (i) symptoms
suggestive of myocardial ischemia or (ii) new ischemic ECG changes or (iii) angiographic findings consistent with a procedural complication or (iv) imaging
demonstration of new loss of viable myocardium or new regional wall motion abnormality are required.
● Stent thrombosis associated with MI when detected by coronary angiography or autopsy in the setting of myocardial ischemia and with a rise and/or fall of cardiac
biomarker values with at least one value above the 99th percentile URL.
● Coronary artery bypass grafting (CABG) related MI is arbitrarily defined by elevation of cardiac biomarker values (10  99th percentile URL) in patients with
normal baseline cTn values (99th percentile URL). In addition, either (i) new pathological Q waves or new LBBB, or (ii) angiographic documented new graft or
new native coronary artery occlusion, or (iii) imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
Criteria for prior myocardial infarction
Any one of the following criteria meets the diagnosis for prior MI:
● Pathological Q waves with or without symptoms in the absence of non-ischemic causes.
● Imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischemic cause.
● Pathological findings of a prior MI.T
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Myocardial infarction (MI) can be recognized by clinical
features, including electrocardiographic (ECG) findings, ele-
vated values of biochemical markers (biomarkers) of myocar-
dial necrosis, and by imaging, or may be defined by pathology.
It is a major cause of death and disability worldwide. MI may
be the first manifestation of coronary artery disease (CAD) or
it may occur, repeatedly, in patients with established disease.
Information on MI rates can provide useful information
regarding the burden of CAD within and across populations,
especially if standardized data are collected in a manner that
distinguishes between incident and recurrent events. From the
epidemiological point of view, the incidence of MI in a
population can be used as a proxy for the prevalence of CAD
in that population. The term ‘myocardial infarction’ may have
major psychological and legal implications for the individual
and society. It is an indicator of one of the leading health
problems in the world and it is an outcome measure in clinical
trials, observational studies and quality assurance programs.
These studies and programs require a precise and consistent
definition of MI.
In the past, a general consensus existed for the clinical
syndrome designated as MI. In studies of disease preva-
lence, the World Health Organization (WHO) defined MI
from symptoms, ECG abnormalities and cardiac enzymes.
However, the development of ever more sensitive and
myocardial tissue-specific cardiac biomarkers and more
sensitive imaging techniques now allows for detection of
very small amounts of myocardial injury or necrosis. Addi- btionally, the management of patients with MI has signifi-
cantly improved, resulting in less myocardial injury and
necrosis, in spite of a similar clinical presentation. More-
over, it appears necessary to distinguish the various condi-
tions which may cause MI, such as ‘spontaneous’ and
‘procedure-related’ MI. Accordingly, physicians, other
healthcare providers and patients require an up-to-date
definition of MI.
In 2000, the First Global MI Task Force presented a new
definition of MI, which implied that any necrosis in the
setting of myocardial ischemia should be labeled as MI (1).
hese principles were further refined by the Second Global
I Task Force, leading to the Universal Definition of
yocardial Infarction Consensus Document in 2007, which
mphasized the different conditions which might lead to an
I (2). This document, endorsed by the European Society
f Cardiology (ESC), the American College of Cardiology
oundation (ACCF), the American Heart Association
AHA), and the World Heart Federation (WHF), has been
ell accepted by the medical community and adopted by the
HO (3). However, the development of even more sensi-
ive assays for markers of myocardial necrosis mandates
urther revision, particularly when such necrosis occurs in
he setting of the critically ill, after percutaneous coronary
rocedures or after cardiac surgery. The Third Global MI
ask Force has continued the Joint ESC/ACCF/AHA/
HF efforts by integrating these insights and new data into
he current document, which now recognizes that very small
mounts of myocardial injury or necrosis can be detected by
iochemical markers and/or imaging.
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myocardial ischemia and infarction
MI is defined in pathology as myocardial cell death due to
prolonged ischemia. After the onset of myocardial isch-
emia, histological cell death is not immediate, but takes a
finite period of time to develop—as little as 20 min, or
less in some animal models (4). It takes several hours
before myocardial necrosis can be identified by macro-
scopic or microscopic post-mortem examination. Com-
plete necrosis of myocardial cells at risk requires at least
2-4 h, or longer, depending on the presence of collateral
circulation to the ischemic zone, persistent or intermit-
tent coronary arterial occlusion, the sensitivity of the
myocytes to ischemia, pre-conditioning, and individual
demand for oxygen and nutrients (2). The entire process
leading to a healed infarction usually takes at least 5-6
weeks. Reperfusion may alter the macroscopic and mi-
croscopic appearance.
Biomarker detection of
myocardial injury with necrosis
Myocardial injury is detected when blood levels of sensitive
and specific biomarkers such as cTn or the MB fraction of
creatine kinase (CKMB) are increased (2). Cardiac troponin
I and T are components of the contractile apparatus of
myocardial cells and are expressed almost exclusively in the
heart. Although elevations of these biomarkers in the
lood reflect injury leading to necrosis of myocardial
ells, they do not indicate the underlying mechanism (5).
arious possibilities have been suggested for release of
tructural proteins from the myocardium, including nor-
al turnover of myocardial cells, apoptosis, cellular
elease of troponin degradation products, increased cel-
ular wall permeability, formation and release of mem-
ranous blebs, and myocyte necrosis (6). Regardless of
he pathobiology, myocardial necrosis due to myocardial
schemia is designated as MI.
Also, histological evidence of myocardial injury with
ecrosis may be detectable in clinical conditions associated
ith predominantly non- ischemic myocardial injury. Small
mounts of myocardial injury with necrosis may be detected,
hich are associated with heart failure (HF), renal failure,
yocarditis, arrhythmias, pulmonary embolism or otherwise
neventful percutaneous or surgical coronary procedures.
hese should not be labeled as MI or a complication of the
rocedures, but rather as myocardial injury, as illustrated in
igure 1. It is recognized that the complexity of clinical
ircumstances may sometimes render it difficult to deter-
ine where individual cases may lie within the ovals of
igure 1. In this setting, it is important to distinguish acute
auses of cTn elevation, which require a rise and/or fall of
Tn values, from chronic elevations that tend not to change
cutely. A list of such clinical circumstances associated with nlevated values of cTn is presented in Table 1. The
ultifactorial contributions resulting in the myocardial
njury should be described in the patient record.
The preferred biomarker—overall and for each specific
ategory of MI—is cTn (I or T), which has high myocardial
issue specificity as well as high clinical sensitivity. Detec-
ion of a rise and/or fall of the measurements is essential to
he diagnosis of acute MI (7). An increased cTn concen-
ration is defined as a value exceeding the 99th percentile of
normal reference population [upper reference limit
URL)]. This discriminatory 99th percentile is designated
s the decision level for the diagnosis of MI and must be
etermined for each specific assay with appropriate quality
ontrol in each laboratory (8,9). The values for the 99th
ercentile URL defined by manufacturers, including those
or many of the high-sensitivity assays in development, can
e found in the package inserts for the assays or in recent
ublications (10–12).
Values should be presented as nanograms per liter (ng/L)
r picograms per milliliter (pg/mL) to make whole num-
ers. Criteria for the rise of cTn values are assay-dependent
ut can be defined from the precision profile of each
ndividual assay, including high-sensitivity assays (10,11).
ptimal precision, as described by coefficient of variation
CV) at the 99th percentile URL for each assay, should be
efined as 10%. Better precision (CV 10%) allows for
ore sensitive assays and facilitates the detection of chang-
ng values (13). The use of assays that do not have optimal
recision (CV 10% at the 99th percentile URL) makes
etermination of a significant change more difficult but does
Figure 1. This illustration shows various clinical entities: for
xample, renal failure, heart failure, tachy- or bradyarrhythmia,
ardiac or non-cardiac procedures that can be associated with
yocardial injury with cell death marked by cardiac troponin ele-
ation. However, these entities can also be associated with myo-
ardial infarction in case of clinical evidence of acute myocardial
schemia with rise and/or fall of cardiac troponin.ot cause false positive results. Assays with CV20% at the
m
p
m
H
i
a
m
s
w
d
C
w
b
1586 Thygesen et al. JACC Vol. 60, No. 16, 2012
Expert Consensus Document October 16, 2012:1581–9899th percentile URL should not be used (13). It is acknowl-
edged that pre-analytic and analytic problems can induce
elevated and reduced values of cTn (10,11).
Blood samples for the measurement of cTn should be
drawn on first assessment and repeated 3-6 h later. Later
samples are required if further ischemic episodes occur, or
when the timing of the initial symptoms is unclear (14). To
establish the diagnosis of MI, a rise and/or fall in values
with at least one value above the decision level is required,
coupled with a strong pre-test likelihood. The demonstration
of a rising and/or falling pattern is needed to distinguish acute-
from chronic elevations in cTn concentrations that are associ-
ated with structural heart disease (10,11,15–19). For example,
patients with renal failure or HF can have significant chronic
elevations in cTn. These elevations can be marked, as seen in
many patients with MI, but do not change acutely (7).
However, a rising or falling pattern is not absolutely
necessary to make the diagnosis of MI if a patient with a
high pre-test risk of MI presents late after symptom onset;
for example, near the peak of the cTn time-concentration
curve or on the slow-declining portion of that curve, when
detecting a changing pattern can be problematic. Values
may remain elevated for 2 weeks or more following the
Table 1. Elevation of Cardiac Troponin Values
Because of Myocardial Injury
Injury related to primary myocardial ischemia
Plaque rupture
Intraluminal coronary artery thrombus formation
Injury related to supply/demand imbalance of myocardial ischemia
Tachy-/brady-arrhythmias
Aortic dissection or severe aortic valve disease
Hypertrophic cardiomyopathy
Cardiogenic, hypovolemic, or septic shock
Severe respiratory failure
Severe anemia
Hypertension with or without LVH
Coronary spasm
Coronary embolism or vasculitis
Coronary endothelial dysfunction without significant CAD
Injury not related to myocardial ischemia
Cardiac contusion, surgery, ablation, pacing, or defibrillator shocks
Rhabdomyolysis with cardiac involvement
Myocarditis
Cardiotoxic agents, e.g. anthracyclines, herceptin
Multifactorial or indeterminate myocardial injury
Heart failure
Stress (Takotsubo) cardiomyopathy
Severe pulmonary embolism or pulmonary hypertension
Sepsis and critically ill patients
Renal failure
Severe acute neurological diseases, e.g. stroke, subarachnoid
hemorrhage
Infiltrative diseases, e.g. amyloidosis, sarcoidosis
Strenuous exerciseonset of myocyte necrosis (10).Sex-dependent values may be recommended for high-
sensitivity troponin assays (20,21). An elevated cTn value
(99th percentile URL), with or without a dynamic pattern
of values or in the absence of clinical evidence of ischemia,
should prompt a search for other diagnoses associated with
myocardial injury, such as myocarditis, aortic dissection,
pulmonary embolism, or HF. Renal failure and other more
non-ischemic chronic disease states, that can be associated
with elevated cTn levels, are listed in Table 1 (10,11).
If a cTn assay is not available, the best alternative is
CKMB (measured by mass assay). As with troponin, an
increased CKMB value is defined as a measurement above
the 99th percentile URL, which is designated as the
decision level for the diagnosis of MI (22). Sex-specific
values should be employed (22).
Clinical features of
myocardial ischemia and infarction
Onset of myocardial ischemia is the initial step in the
development of MI and results from an imbalance between
oxygen supply and demand. Myocardial ischemia in a
clinical setting can usually be identified from the patient’s
history and from the ECG. Possible ischemic symptoms
include various combinations of chest, upper extremity,
mandibular or epigastric discomfort (with exertion or at
rest) or an ischemic equivalent such as dyspnea or fatigue.
The discomfort associated with acute MI usually lasts 20
in. Often, the discomfort is diffuse—not localized, nor
ositional, nor affected by movement of the region—and it
ay be accompanied by diaphoresis, nausea or syncope.
owever, these symptoms are not specific for myocardial
schemia. Accordingly, they may be misdiagnosed and
ttributed to gastrointestinal, neurological, pulmonary or
usculoskeletal disorders. MI may occur with atypical
ymptoms—such as palpitations or cardiac arrest—or even
ithout symptoms; for example in women, the elderly,
iabetics, or post-operative and critically ill patients (2).
areful evaluation of these patients is advised, especially
hen there is a rising and/or falling pattern of cardiac
iomarkers.
Clinical classification
of myocardial infarction
For the sake of immediate treatment strategies, such as
reperfusion therapy, it is usual practice to designate MI in
patients with chest discomfort, or other ischemic symptoms
that develop ST elevation in two contiguous leads (see ECG
section), as an ‘ST elevation MI’ (STEMI). In contrast,
patients without ST elevation at presentation are usually
designated as having a ‘non-ST elevation MI’ (NSTEMI).
Many patients with MI develop Q waves (Q wave MI), but
others do not (non-Q MI). Patients without elevated bio-
marker values can be diagnosed as having unstable angina. In
t1587JACC Vol. 60, No. 16, 2012 Thygesen et al.
October 16, 2012:1581–98 Expert Consensus Documentaddition to these categories, MI is classified into various types,
based on pathological, clinical and prognostic differences, along
with different treatment strategies (Table 2).
Spontaneous myocardial infarction (MI type 1)
This is an event related to atherosclerotic plaque rupture,
ulceration, fissuring, erosion, or dissection with resulting
intraluminal thrombus in one or more of the coronary
arteries, leading to decreased myocardial blood flow or distal
platelet emboli with ensuing myocyte necrosis. The patient
may have underlying severe CAD but, on occasion (5 to
20%), non-obstructive or no CAD may be found at angiog-
raphy, particularly in women (23–25).
Myocardial infarction secondary
to an ischemic imbalance (MI type 2)
In instances of myocardial injury with necrosis, where a
condition other than CAD contributes to an imbalance
between myocardial oxygen supply and/or demand, the term
‘MI type 2’ is employed (Figure 2). In critically ill patients,
or in patients undergoing major (non-cardiac) surgery,
elevated values of cardiac biomarkers may appear, due to the
direct toxic effects of endogenous or exogenous high circu-
lating catecholamine levels. Also coronary vasospasm and/or
endothelial dysfunction have the potential to cause MI
(26–28).
Cardiac death due to
myocardial infarction (MI type 3)
Patients who suffer cardiac death, with symptoms suggestive
of myocardial ischemia accompanied by presumed new
ischemic ECG changes or new LBBB—but without avail-
Table 2. Universal Classification of Myocardial Infarction
Type 1: Spontaneous myocardial infarction
Spontaneous myocardial infarction related to atherosclerotic plaque rupture,
one or more of the coronary arteries leading to decreased myocardial bloo
underlying severe CAD but on occasion non-obstructive or no CAD.
Type 2: Myocardial infarction secondary to an ischemic imbalance
In instances of myocardial injury with necrosis where a condition other than C
e.g. coronary endothelial dysfunction, coronary artery spasm, coronary em
hypertension with or without LVH.
Type 3: Myocardial infarction resulting in death when biomarker values are una
Cardiac death with symptoms suggestive of myocardial ischemia and presum
samples could be obtained, before cardiac biomarker could rise, or in rare
Type 4a: Myocardial infarction related to percutaneous coronary intervention (PC
Myocardial infarction associated with PCI is arbitrarily defined by elevation of
(99th percentile URL) or a rise of cTn values 20% if the baseline values
myocardial ischemia, or (ii) new ischemic ECG changes or new LBBB, or (ii
persistent slow- or no-flow or embolization, or (iv) imaging demonstration o
required.
Type 4b: Myocardial infarction related to stent thrombosis
Myocardial infarction associated with stent thrombosis is detected by coronar
and/ or fall of cardiac biomarkers values with at least one value above the
Type 5: Myocardial infarction related to coronary artery bypass grafting (CABG)
Myocardial infarction associated with CABG is arbitrarily defined by elevation
baseline cTn values (99th percentile URL). In addition, either (i) new path
native coronary artery occlusion, or (iii) imaging evidence of new loss of viaable biomarker values—represent a challenging diagnosticgroup. These individuals may die before blood samples for
biomarkers can be obtained, or before elevated cardiac
biomarkers can be identified. If patients present with clinical
features of myocardial ischemia, or with presumed new
ischemic ECG changes, they should be classified as having
had a fatal MI, even if cardiac biomarker evidence of MI is
lacking.
Myocardial infarction associated with
revascularization procedures (MI types 4 and 5)
Periprocedural myocardial injury or infarction may occur at
some stages in the instrumentation of the heart that is
required during mechanical revascularization procedures,
either by PCI or by coronary artery bypass grafting
(CABG). Elevated cTn values may be detected following
tion, Assuring, erosion, or dissection with resulting intraluminal thrombus in
or distal platelet emboli with ensuing myocyte necrosis. The patient may have
ntributes to an imbalance between myocardial oxygen supply and/or demand,
, tachy-/brady-arrhythmias, anemia, respiratory failure, hypotension, and
le
w ischemic ECG changes or new LBBB, but death occurring before blood
cardiac biomarkers were not collected.
lues 5 x 99th percentile URL in patients with normal baseline values
levated and are stable or falling. In addition, either (i) symptoms suggestive of
iographic loss of patency of a major coronary artery or a side branch or
loss of viable myocardium or new regional wall motion abnormality are
iography or autopsy in the setting of myocardial ischemia and with a rise
percentile URL.
diac biomarker values 10 x 99th percentile URL in patients with normal
al Q waves or new LBBB, or (ii) angiographic documented new graft or new
yocardium or new regional wall motion abnormality.
Figure 2. Differentiation between myocardial infarction (MI)
ypes 1 and 2 according to the condition of the coronary arteries.ulcera
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lead to myocardial injury with necrosis (29–32). It is likely
that limitation of such injury is beneficial to the patient:
however, a threshold for a worsening prognosis, related to
an asymptomatic increase of cardiac biomarker values in the
absence of procedural complications, is not well defined
(33–35). Subcategories of PCI-related MI are connected to
stent thrombosis and restenosis that may happen after the
primary procedure.
Electrocardiographic
detection of myocardial infarction
The ECG is an integral part of the diagnostic work-up of
patients with suspected MI and should be acquired and
interpreted promptly (i.e. target within 10 min) after clinical
presentation (2). Dynamic changes in the ECG waveforms
during acute myocardial ischemic episodes often require
acquisition of multiple ECGs, particularly if the ECG at
initial presentation is non-diagnostic. Serial recordings in
symptomatic patients with an initial non-diagnostic ECG
should be performed at 15–30 min intervals or, if available,
continuous computer-assisted 12-lead ECG recording. Re-
currence of symptoms after an asymptomatic interval are an
indication for a repeat tracing and, in patients with evolving
ECG abnormalities, a pre-discharge ECG should be ac-
quired as a baseline for future comparison. Acute or evolving
changes in the ST-T waveforms and Q waves, when
present, potentially allow the clinician to time the event, to
identify the infarct-related artery, to estimate the amount of
myocardium at risk as well as prognosis, and to determine
therapeutic strategy. More profound ST-segment shift or T
wave inversion involving multiple leads/territories is associ-
ated with a greater degree of myocardial ischemia and a
worse prognosis. Other ECG signs associated with acute
myocardial ischemia include cardiac arrhythmias, intraven-
tricular and atrioventricular conduction delays, and loss of
pre-cordial R wave amplitude. Coronary artery size and
distribution of arterial segments, collateral vessels, location,
extent and severity of coronary stenosis, and prior myocar-
dial necrosis can all impact ECG manifestations of myo-
cardial ischemia (36). Therefore the ECG at presentation
should always be compared to prior ECG tracings, when
available. The ECG by itself is often insufficient to diagnose
acute myocardial ischemia or infarction, since ST deviation
may be observed in other conditions, such as acute pericar-
ditis, left ventricular hypertrophy (LVH), left bundle branch
block (LBBB), Brugada syndrome, stress cardiomyopathy,
and early repolarization patterns (37). Prolonged new ST-
segment elevation (e.g. 20 min), particularly when asso-
ciated with reciprocal ST-segment depression, usually re-
flects acute coronary occlusion and results in myocardial
injury with necrosis. As in cardiomyopathy, Q waves may
also occur due to myocardial fibrosis in the absence of CAD. wECG abnormalities of myocardial ischemia or infarction
may be inscribed in the PR segment, the QRS complex, the
ST-segment or the T wave. The earliest manifestations of
myocardial ischemia are typically T wave and ST-segment
changes. Increased hyperacute T wave amplitude, with
prominent symmetrical T waves in at least two contiguous
leads, is an early sign that may precede the elevation of the
ST-segment. Transient Q waves may be observed during an
episode of acute ischemia or (rarely) during acute MI with
successful reperfusion. Table 3 lists ST-T wave criteria for
the diagnosis of acute myocardial ischemia that may or may
not lead to MI. The J point is used to determine the
magnitude of the ST-segment shift. New, or presumed new,
J point elevation0.1 mV is required in all leads other than
V2 and V3. In healthy men under age 40, J-point elevation
can be as much as 0.25 mV in leads V2 or V3, but it
ecreases with increasing age. Sex differences require differ-
nt cut-points for women, since J point elevation in healthy
omen in leads V2 and V3 is less than in men (38).
Contiguous leads’ refers to lead groups such as anterior
eads (V1–V6), inferior leads (II, III, aVF) or lateral/apical
leads (I, aVL). Supplemental leads such as V3R and V4R
reflect the free wall of the right ventricle and V7–V9 the
inferobasal wall.
The criteria in Table 3 require that the ST shift be
present in two or more contiguous leads. For example,0.2
mV of ST elevation in lead V2, and 0.1 mV in lead V1,
would meet the criteria of two abnormal contiguous leads in
a man 40 years old. However, 0.1 mV and 0.2 mV of
T elevation, seen only in leads V2–V3 in men (or 0.15
V in women), may represent a normal finding. It should
e noted that, occasionally, acute myocardial ischemia may
reate sufficient ST-segment shift to meet the criteria in one
ead but have slightly less than the required ST shift in a
ontiguous lead. Lesser degrees of ST displacement or T
ave inversion do not exclude acute myocardial ischemia or
volving MI, since a single static recording may miss the
ore dynamic ECG changes that might be detected with
erial recordings. ST elevation or diagnostic Q waves in
ontiguous lead groups are more specific than ST depression
n localizing the site of myocardial ischemia or necrosis
39,40). Supplemental leads, as well as serial ECG record-
ngs, should always be considered in patients that present
Table 3. ECG Manifestations of Acute
Myocardial Ischemia (in Absence of LVH and LBBB)
ST elevation
New ST elevation at the J point in two contiguous leads with the cut-points:
0.1 mV in all leads other than leads V2–V3 where the following cut
points apply: 0.2 mV in men 40 years; 0.25 mV in men 40 years,
or 0.15 mV in women.
ST depression and T wave changes
New horizontal or down-sloping ST depression 0.05 mV in two contiguous
leads and/or T inversion 0.1 mV in two contiguous leads with
prominent R wave or R/S ratio 1.ith ischemic chest pain and a non-diagnostic initial ECG
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emia in the distribution of a left circumflex artery is often
overlooked and is best captured using posterior leads at the
fifth intercostal space (V7 at the left posterior axillary line,
8 at the left mid-scapular line, and V9 at the left paraspinal
border). Recording of these leads is strongly recommended
in patients with high clinical suspicion for acute circumflex
occlusion (for example, initial ECG non-diagnostic, or
ST-segment depression in leads V1–V3). A cut-point of
0.05 mV ST elevation is recommended in leads V7–V9;
specificity is increased at a cut-point 0.1 mV ST elevation
and this cut-point should be used in men40 years old. ST
depression in leads V1–V3 may be suggestive of inferobasal
yocardial ischemia (posterior infarction), especially when
he terminal T wave is positive (ST elevation equivalent),
owever this is non-specific (41–43). In patients with
nferior and suspected right ventricular infarction, right
re-cordial leads V3R and V4R should be recorded, since ST
elevation 0.05 mV (0.1 mV in men 30 years old)
provides supportive criteria for the diagnosis (42).
During an episode of acute chest discomfort, pseudo-
normalization of previously inverted T waves may indicate
acute myocardial ischemia. Pulmonary embolism, intracra-
nial processes, electrolyte abnormalities, hypothermia, or
peri-/myocarditis may also result in ST-T abnormalities and
should be considered in the differential diagnosis. The
diagnosis of MI is more difficult in the presence of LBBB
(44,45). However, concordant ST-segment elevation or a
previous ECG may be helpful to determine the presence of
acute MI in this setting. In patients with right bundle
branch block (RBBB), ST-T abnormalities in leads V1–V3
are common, making it difficult to assess the presence of
ischemia in these leads: however, when new ST elevation or
Q waves are found, myocardial ischemia or infarction
should be considered.
Prior myocardial infarction
As shown in Table 4, Q waves or QS complexes in the
bsence of QRS confounders are pathognomonic of a prior
I in patients with ischemic heart disease, regardless of
ymptoms (46,47). The specificity of the ECG diagnosis for
I is greatest when Q waves occur in several leads or lead
roupings. When the Q waves are associated with ST
eviations or T wave changes in the same leads, the
Table 4. ECG Changes
Associated With Prior Myocardial Infarction
Any Q wave in leads V2–V3 0.02 sec or QS complex in leads V2 and Vr
Q wave 0.03 sec and 0.1 mV deep or QS complex in leads 1, II, aVL,
aVF or V4–V6 in any two leads of a contiguous lead grouping
(1, aVL; V1–V6; II, III, aVF).
a
R wave 0.04 sec in V1–V2 and R/S 1 with a concordant positive T wave in
absence of conduction defect.
aThe same criteria are used for supplemental leads V7–V9.ikelihood of MI is increased; for example, minor Q waves0.02 sec and 0.03 sec that are 0.1 mV deep are
suggestive of prior MI if accompanied by inverted T waves
in the same lead group. Other validated MI coding
algorithms, such as the Minnesota Code and WHO
MONICA, have been used in epidemiological studies
and clinical trials (3).
Silent myocardial infarction
Asymptomatic patients who develop new pathologic Q
wave criteria for MI detected during routine ECG follow-
up, or reveal evidence of MI by cardiac imaging, that cannot
be directly attributed to a coronary revascularization proce-
dure, should be termed ‘silent MI’ (48–51). In studies, silent
Q wave MI accounted for 9-37% of all non-fatal MI events
and were associated with a significantly increased mortality
risk (48,49). Improper lead placement or QRS confounders
may result in what appear to be new Q waves or QS
complexes, as compared to a prior tracing. Thus, the
diagnosis of a new silent Q wave MI should be confirmed by
a repeat ECG with correct lead placement, or by an imaging
study, and by focused questioning about potential interim
ischemic symptoms.
Conditions that confound the
ECG diagnosis of myocardial infarction
A QS complex in lead V1 is normal. A Q wave 0.03 sec
and 25% of the R wave amplitude in lead III is normal if
the frontal QRS axis is between30° and 0°. A Q wave may
also be normal in aVL if the frontal QRS axis is between 60°
and 90°. Septal Q waves are small, non-pathological Q
waves 0.03 sec and 25% of the R-wave amplitude in
leads I, aVL, aVF, and V4–V6. Pre-excitation, obstructive,
ilated or stress cardiomyopathy, cardiac amyloidosis,
BBB, left anterior hemiblock, LVH, right ventricular
ypertrophy, myocarditis, acute cor pulmonale, or hyperka-
emia may be associated with Q waves or QS complexes in
he absence of MI. ECG abnormalities that mimic myo-
ardial ischemia or MI are presented in Table 5.
Imaging techniques
Non-invasive imaging plays many roles in patients with
known or suspected MI, but this section concerns only its
role in the diagnosis and characterization of MI. The
underlying rationale is that regional myocardial hypoperfu-
sion and ischemia lead to a cascade of events, including
myocardial dysfunction, cell death and healing by fibrosis.
Important imaging parameters are therefore perfusion,
myocyte viability, myocardial thickness, thickening and
motion, and the effects of fibrosis on the kinetics of
paramagnetic or radio-opaque contrast agents.
Commonly used imaging techniques in acute and chronic
infarction are echocardiography, radionuclide ventriculog-
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gle photon emission computed tomography (SPECT), and
magnetic resonance imaging (MRI). Positron emission
tomography (PET) and X-ray computed tomography (CT)
are less common (52). There is considerable overlap in their
capabilities and each of the techniques can, to a greater or
lesser extent, assess myocardial viability, perfusion, and
function. Only the radionuclide techniques provide a direct
assessment of myocyte viability, because of the inherent
properties of the tracers used. Other techniques provide
indirect assessments of myocardial viability, such as contrac-
tile response to dobutamine by echocardiography or myo-
cardial fibrosis by MR.
Echocardiography
The strength of echocardiography is the assessment of
cardiac structure and function, in particular myocardial
thickness, thickening and motion. Echocardiographic con-
trast agents can improve visualization of the endocardial
border and can be used to assess myocardial perfusion and
microvascular obstruction. Tissue Doppler and strain imag-
ing permit quantification of global and regional function
(53). Intravascular echocardiographic contrast agents have
been developed that target specific molecular processes, but
these techniques have not yet been applied in the setting of
MI (54).
Radionuclide imaging
Several radionuclide tracers allow viable myocytes to be
imaged directly, including the SPECT tracers thallium-201,
technetium-99m MIBI and tetrofosmin, and the PET
tracers F-2-fluorodeoxyglucose (FDG) and rubidium-82
(18,52). The strength of the SPECT techniques is that
these are the only commonly available direct methods of
assessing viability, although the relatively low resolution
of the images leaves them at a disadvantage for detecting
Table 5. Common ECG Pitfalls
in Diagnosing Myocardial Infarction
False positives
● Early repolarization
● LBBB
● Pre-excitation
● J point elevation syndromes, e.g. Brugada syndrome
● Peri-/myocarditis
● Pulmonary embolism
● Subarachnoid hemorrhage
● Metabolic disturbances such as hyperkalemia
● Cardiomyopathy
● Lead transposition
● Cholecystitis
● Persistent juvenile pattern
● Malposition of precordial ECG electrodes
● Tricyclic antidepressants or phenothiazines
False negatives
● Prior Ml with Q-waves and/or persistent ST elevation
● Right ventricular pacing
● LBBBsmall areas of MI. The common SPECT radiopharma-ceuticals are also tracers of myocardial perfusion and the
techniques thereby readily detect areas of MI and induc-
ible perfusion abnormalities. ECG-gated imaging pro-
vides a reliable assessment of myocardial motion, thick-
ening and global function. Evolving radionuclide
techniques that are relevant to the assessment of MI
include imaging of sympathetic innervation using iodine-
123-labelled meta-iodo-benzylguanidine (mIBG) (55),
imaging of matrix metalloproteinase activation in ven-
tricular remodeling (56,57), and refined assessment of
myocardial metabolism (58).
Magnetic resonance imaging
The high tissue contrast of cardiovascular MRI provides an
accurate assessment of myocardial function and it has
similar capability to echocardiography in suspected acute
MI. Paramagnetic contrast agents can be used to assess
myocardial perfusion and the increase in extracellular space
that is associated with the fibrosis of prior MI. These
techniques have been used in the setting of acute MI
(59,60), and imaging of myocardial fibrosis by delayed
contrast enhancement is able to detect even small areas of
subendocardial MI. It is also of value in detecting
myocardial disease states that can mimic MI, such as
myocarditis (61).
Computed tomography
Infarcted myocardium is initially visible as a focal area of
decreased left ventricle (LV) enhancement, but later imag-
ing shows hyper-enhancement, as with late gadolinium
imaging by MRI (62). This finding is clinically relevant
because contrast-enhanced CT may be performed for sus-
pected pulmonary embolism and aortic dissection—
conditions with clinical features that overlap with those of
acute MI—but the technique is not used routinely. Simi-
larly, CT assessment of myocardial perfusion is technically
feasible but not yet fully validated.
Applying imaging in acute myocardial infarction
Imaging techniques can be useful in the diagnosis of acute
MI because of their ability to detect wall motion abnormal-
ities or loss of viable myocardium in the presence of elevated
cardiac biomarker values. If, for some reason, biomarkers
have not been measured or may have normalized, demon-
stration of new loss of myocardial viability in the absence of
non-ischemic causes meets the criteria for MI. Normal
function and viability have a very high negative predictive
value and practically exclude acute MI (63). Thus, imaging
techniques are useful for early triage and discharge of
patients with suspected MI. However, if biomarkers have
been measured at appropriate times and are normal, this
excludes an acute MI and takes precedence over the imaging
criteria.
Abnormal regional myocardial motion and thickening
may be caused by acute MI or by one or more of several
other conditions, including prior MI, acute ischemia, stun-
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October 16, 2012:1581–98 Expert Consensus Documentning or hibernation. Non-ischemic conditions, such as
cardiomyopathy and inflammatory or infiltrative diseases,
can also lead to regional loss of viable myocardium or
functional abnormality. Therefore, the positive predictive
value of imaging for acute MI is not high unless these
conditions can be excluded, and unless a new abnormality is
detected or can be presumed to have arisen in the setting of
other features of acute MI.
Echocardiography provides an assessment of many non-
ischemic causes of acute chest pain, such as peri-
myocarditis, valvular heart disease, cardiomyopathy, pulmo-
nary embolism or aortic dissection (53). It is the imaging
technique of choice for detecting complications of acute MI,
including myocardial free wall rupture, acute ventricular
septal defect, and mitral regurgitation secondary to papillary
muscle rupture or ischemia.
Radionuclide imaging can be used to assess the amount of
myocardium that is salvaged by acute revascularization (64).
Tracer is injected at the time of presentation, with imaging
deferred until after revascularization, providing a measure of
myocardium at risk. Before discharge, a second resting
injection provides a measure of final infarct size, and the
difference between the two corresponds to the myocardium
that has been salvaged.
Applying imaging in late
presentation of myocardial infarction
In case of late presentation after suspected MI, the presence
of regional wall motion abnormality, thinning or scar in the
absence of non- ischemic causes, provides evidence of past
MI. The high resolution and specificity of late gadolinium
enhancement MRI for the detection of myocardial fibrosis
has made this a very valuable technique. In particular, the
ability to distinguish between subendocardial and other
patterns of fibrosis provides a differentiation between isch-
emic heart disease and other myocardial abnormalities.
Imaging techniques are also useful for risk stratification after
a definitive diagnosis of MI. The detection of residual or
remote ischemia and/or ventricular dysfunction provides
powerful indicators of later outcome.
Diagnostic criteria for
myocardial infarction with PCI (MI type 4)
Balloon inflation during PCI often causes transient isch-
emia, whether or not it is accompanied by chest pain or
ST-T changes. Myocardial injury with necrosis may result
from recognizable peri-procedural events—alone or in com-
bination—such as coronary dissection, occlusion of a major
coronary artery or a side-branch, disruption of collateral
flow, slow flow or no-reflow, distal embolization, and
microvascular plugging. Embolization of intracoronary
thrombus or atherosclerotic particulate debris may not be
preventable, despite current anticoagulant and antiplate-
let adjunctive therapy, aspiration or protection devices. cSuch events induce inflammation of the myocardium
surrounding islets of myocardial necrosis (65). New areas
of myocardial necrosis have been demonstrated by MRI
following PCI (66).
The occurrence of procedure-related myocardial cell in-
jury with necrosis can be detected by measurement of
cardiac biomarkers before the procedure, repeated 3–6 h
later and, optionally, further re-measurement 12 h thereaf-
ter. Increasing levels can only be interpreted as procedure-
related myocardial injury if the pre-procedural cTn value is
normal (99th percentile URL) or if levels are stable or
falling (67,68). In patients with normal pre-procedural
values, elevation of cardiac biomarker values above the 99th
percentile URL following PCI are indicative of procedure-
related myocardial injury. In earlier studies, increased values
of post-procedural cardiac biomarkers, especially CKMB,
were associated with impaired outcome (69,70). However,
when cTn concentrations are normal before PCI and
become abnormal after the procedure, the threshold above
the 99th percentile URL—whereby an adverse prognosis is
evident—is not well defined (71) and it is debatable whether
such a threshold even exists (72). If a single baseline cTn
value is elevated, it is impossible to determine whether
further increases are due to the procedure or to the initial
process causing the elevation. In this situation, it appears
that the prognosis is largely determined by the pre-
procedural cTn level (71). These relationships will probably
become even more complex for the new high-sensitivity
troponin assays (70).
In patients undergoing PCI with normal (99th percen-
tile URL) baseline cTn concentrations, elevations of cTn
5  99th percentile URL occurring within 48 h of the
procedure—plus either (i) evidence of prolonged ischemia
(20 min) as demonstrated by prolonged chest pain, or
(ii) ischemic ST changes or new pathological Q waves, or
(iii) angiographic evidence of a flow limiting complication,
such as of loss of patency of a side branch, persistent
slow-flow or no-reflow, embolization, or (iv) imaging evi-
dence of new loss of viable myocardium or new regional wall
motion abnormality—is defined as PCI-related MI (type
4a). This threshold of cTn values 5  99th percentile
RL is arbitrarily chosen, based on clinical judgment and
ocietal implications of the label of peri-procedural MI.
hen a cTn value is 5  99th percentile URL after PCI
nd the cTn value was normal before the PCI—or when the
Tn value is 5  99th percentile URL in the absence of
schemic, angiographic or imaging findings—the term
myocardial injury’ should be used.
If the baseline cTn values are elevated and are stable or
alling, then a rise of 20% is required for the diagnosis of
type 4a MI, as with reinfarction. Recent data suggest that,
hen PCI is delayed after MI until biomarker concentra-
ions are falling or have normalized, and elevation of cardiac
iomarker values then reoccurs, this may have some long-
erm significance. However, additional data are needed to
onfirm this finding (73).
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documented by angiography and/or at autopsy and a rise
and/or fall of cTn values 99th percentile URL (identified
as MI type 4b). In order to stratify the occurrence of stent
thrombosis in relation to the timing of the PCI procedure,
the Academic Research Consortium recommends temporal
categories of ‘early’ (0 to 30 days), ‘late’ (31 days to 1 year),
and ‘very late’ (1 year) to distinguish likely differences in
the contribution of the various pathophysiological processes
during each of these intervals (74). Occasionally, MI occurs
in the clinical setting of what appears to be a stent
thrombosis: however, at angiography, restenosis is observed
without evidence of thrombus (see section on clinical trials).
Diagnostic criteria for myocardial
infarction with CABG (MI type 5)
During CABG, numerous factors can lead to periprocedural
myocardial injury with necrosis. These include direct myo-
cardial trauma from (i) suture placement or manipulation of
the heart, (ii) coronary dissection, (iii) global or regional
ischemia related to inadequate intra-operative cardiac
protection, (iv) microvascular events related to reperfu-
sion, (v) myocardial injury induced by oxygen free radical
eneration, or (vi) failure to reperfuse areas of the myocar-
ium that are not subtended by graftable vessels (75–77).
RI studies suggest that most necrosis in this setting is not
ocal but diffuse and localized in the subendocardium (78).
In patients with normal values before surgery, any in-
crease of cardiac biomarker values after CABG indicates
myocardial necrosis, implying that an increasing magnitude
of biomarker concentrations is likely to be related to an
impaired outcome. This has been demonstrated in clinical
studies employing CKMB, where elevations 5, 10 and 20
times the URL after CABG were associated with worsened
prognosis; similarly, impaired outcome has been reported
when cTn values were elevated to the highest quartile or
quintile of the measurements (79–83). Unlike prognosis,
scant literature exists concerning the use of biomarkers for
defining an MI related to a primary vascular event in a graft
or native vessel in the setting of CABG. In addition, when
the baseline cTn value is elevated (99th percentile URL),
higher levels of biomarker values are seen post-CABG.
Therefore, biomarkers cannot stand alone in diagnosing MI
in this setting. In view of the adverse impact on survival
observed in patients with significant elevation of bio-
marker concentrations, this Task Force suggests, by
arbitrary convention, that cTn values 10 x 99th percen-
tile URL during the first 48 h following CABG, occur-
ring from a normal baseline cTn value (99th percentile
URL). In addition, either (i) new pathological Q waves or
new LBBB, or (ii) angiographically documented new graft
or new native coronary artery occlusion, or (iii) imaging
evidence of new loss of viable myocardium or new regional
wall motion abnormality, should be considered as diagnosticof a CABG-related MI (type 5). Cardiac biomarker release
is considerably higher after valve replacement with CABG
than with bypass surgery alone, and with on-pump CABG
compared to off-pump CABG (84). The threshold de-
scribed above is more robust for isolated on-pump CABG.
As for PCI, the existing principles from the universal
definition of MI should be applied for the definition of MI
48 h after surgery.
Assessment of MI in patients
undergoing other cardiac procedures
New ST-T abnormalities are common in patients who
undergo cardiac surgery. When new pathological Q waves
appear in different territories than those identified before
surgery, MI (types 1 or 2) should be considered, particularly
if associated with elevated cardiac biomarker values, new
wall motion abnormalities or hemodynamic instability.
Novel procedures such as transcatheter aortic valve im-
plantation (TAVI) or mitral clip may cause myocardial
injury with necrosis, both by direct trauma to the myocar-
dium and by creating regional ischemia from coronary
obstruction or embolization. It is likely that, similarly to
CABG, the more marked the elevation of the biomarker
values, the worse the prognosis—but data on that are not
available.
Modified criteria have been proposed for the diagnosis of
periprocedural MI 72 h after aortic valve implantation
(85). However, given that there is too little evidence, it
appears reasonable to apply the same criteria for procedure-
related MI as stated above for CABG.
Ablation of arrhythmias involves controlled myocardial
injury with necrosis, by application of warming or cooling of
the tissue. The extent of the injury with necrosis can be
assessed by cTn measurement: however, an elevation of cTn
values in this context should not be labeled as MI.
Myocardial infarction
associated with non-cardiac procedures
Perioperative MI is the most common major perioperative
vascular complication in major non-cardiac surgery, and is
associated with a poor prognosis (86,87). Most patients who
have a perioperative MI will not experience ischemic symp-
toms. Nevertheless, asymptomatic perioperative MI is as
strongly associated with 30-day mortality, as is symptomatic
MI (86). Routine monitoring of cardiac biomarkers in
high-risk patients, both prior to and 48–72 h after major
surgery, is therefore recommended. Measurement of high-
sensitivity cTn in post-operative samples reveals that 45% of
patients have levels above the 99th percentile URL and 22%
have an elevation and a rising pattern of values indicative of
evolving myocardial necrosis (88). Studies of patients un-
dergoing major non-cardiac surgery strongly support the
idea that many of the infarctions diagnosed in this context
1593JACC Vol. 60, No. 16, 2012 Thygesen et al.
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oxygen supply and demand, against a background of CAD
(89,90). Together with a rise and/or fall of cTn values, this
indicates MI type 2. However, one pathological study of
fatal perioperative MI patients showed plaque rupture and
platelet aggregation, leading to thrombus formation, in
approximately half of such events (91), that is to say, MI
type 1. Given the differences that probably exist in the
therapeutic approaches to each, close clinical scrutiny and
judgment is needed.
Myocardial infarction
in the intensive care unit
Elevations of cTn values are common in patients in the
intensive care unit and are associated with adverse progno-
sis, regardless of the underlying disease state (92,93). Some
elevations may reflect MI type 2 due to underlying CAD
and increased myocardial oxygen demand (94). Other pa-
tients may have elevated values of cardiac biomarkers, due to
myocardial injury with necrosis induced by catecholamine or
direct toxic effect from circulating toxins. Moreover, in
some patients, MI type 1 may occur. It is often a challenge
for the clinician, caring for a critically ill patient with severe
single organ or multi-organ pathology, to decide on a plan
of action when the patient has elevated cTn values. If and
when the patient recovers from the critical illness, clinical
judgment should be employed to decide whether—and to
what extent—further evaluation for CAD or structural heart
disease is indicated (95).
Recurrent myocardial infarction
‘Incident MI’ is defined as the individual’s first MI. When
features of MI occur in the first 28 days after an incident
event, this is not counted as a new event for epidemiological
purposes. If characteristics of MI occur after 28 days
following an incident MI, it is considered to be a recurrent
MI (3).
Reinfarction
The term ‘reinfarction’ is used for an acute MI that occurs
within 28 days of an incident or recurrent MI (3). The ECG
diagnosis of suspected reinfarction following the initial MI
may be confounded by the initial evolutionary ECG
changes. Reinfarction should be considered when ST ele-
vation 0.1 mV recurs, or new pathognomonic Q waves
appear, in at least two contiguous leads, particularly when
associated with ischemic symptoms for 20 min or longer.
Re-elevation of the ST-segment can, however, also be seen
in threatened myocardial rupture and should lead to addi-
tional diagnostic workup. ST depression or LBBB alone are
non-specific findings and should not be used to diagnose
reinfarction.In patients in whom reinfarction is suspected from
clinical signs or symptoms following the initial MI, an
immediate measurement of cTn is recommended. A second
sample should be obtained 3–6 h later. If the cTn concen-
tration is elevated, but stable or decreasing at the time of
suspected reinfarction, the diagnosis of reinfarction requires
a 20% or greater increase of the cTn value in the second
sample. If the initial cTn concentration is normal, the
criteria for new acute MI apply.
Myocardial injury or infarction
associated with heart failure
Depending on the assay used, detectable-to-clearly elevated
cTn values, indicative of myocardial injury with necrosis,
may be seen in patients with HF syndrome (96). Using
high-sensitivity cTn assays, measurable cTn concentrations
may be present in nearly all patients with HF, with a
significant percentage exceeding the 99th percentile URL,
particularly in those with more severe HF syndrome, such as
in acutely decompensated HF (97).
Whilst MI type 1 is an important cause of acutely
decompensated HF—and should always be considered in
the context of an acute presentation—elevated cTn values
alone, in a patient with HF syndrome, do not establish the
diagnosis of MI type 1 and may, indeed, be seen in those
with non-ischemic HF. Beyond MI type 1, multiple mech-
anisms have been invoked to explain measurable-to-
pathologically elevated cTn concentrations in patients with
HF (96,97). For example, MI type 2 may result from
increased transmural pressure, small-vessel coronary ob-
struction, endothelial dysfunction, anemia or hypotension.
Besides MI type 1 or 2, cardiomyocyte apoptosis and
autophagy due to wall stretch has been experimentally
demonstrated. Direct cellular toxicity related to inflamma-
tion, circulating neurohormones, infiltrative processes, as
well as myocarditis and stress cardiomyopathy, may present
with HF and abnormal cTn measurement (97).
Whilst prevalent and complicating the diagnosis of MI,
the presence, magnitude and persistence of cTn elevation in
HF is increasingly accepted to be an independent predictor
of adverse outcomes in both acute and chronic HF syn-
drome, irrespective of mechanism, and should not be
discarded as ‘false positive’ (97,98).
In the context of an acutely decompensated HF presen-
tation, cTn I or T should always be promptly measured and
ECG recorded, with the goal of identifying or excluding MI
type 1 as the precipitant. In this setting, elevated cTn values
should be interpreted with a high level of suspicion for MI
type 1 if a significant rise and/or fall of the marker are seen,
or if it is accompanied by ischemic symptoms, new ischemic
ECG changes or loss of myocardial function on non-
invasive testing. Coronary artery anatomy may often be
well-known; such knowledge may be used to interpret
abnormal troponin results. If normal coronary arteries are
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for troponin release may be invoked (97).
On the other hand, when coronary anatomy is not
established, the recognition of a cTn value in excess of the
99th percentile URL alone is not sufficient to make a
diagnosis of acute MI due to CAD, nor is it able to identify
the mechanism for the abnormal cTn value. In this setting,
further information, such as myocardial perfusion studies,
coronary angiography, or MRI is often required to better
understand the cause of the abnormal cTn measurement.
However, it may be difficult to establish the reason for cTn
abnormalities, even after such investigations (96,97).
Application of MI in clinical trials
and quality assurance programs
In clinical trials, MI may be an entry criterion or an
end-point. A universal definition for MI is of great benefit
for clinical studies, since it will allow a standardized ap-
proach for interpretation and comparison across different
trials. The definition of MI as an entry criterion, e.g. MI
type 1 and not MI type 2, will determine patient character-
istics in the trial. Occasionally MI occurs and, at angiogra-
phy, restenosis is the only angiographic explanation
(99,100). This PCI-related MI type might be designated as
an ‘MI type 4c’, defined as 50% stenosis at coronary
angiography or a complex lesion associated with a rise
and/or fall of cTn values 99th percentile URL and no other
ignificant obstructive CAD of greater severity following:
i) initially successful stent deployment or (ii) dilatation of a
oronary artery stenosis with balloon angioplasty (50%).
In recent investigations, different MI definitions have
een employed as trial outcomes, thereby hampering com-
arison and generalization between these trials. Consistency
mong investigators and regulatory authorities, with regard
o the definition of MI used as an endpoint in clinical
nvestigations, is of substantial value. Adaptation of the
efinition to an individual clinical study may be appropriate
n some circumstances and should have a well-articulated
ationale. No matter what, investigators should ensure that
trial provides comprehensive data for the various types of
Table 6. Tabulation in Clinical Trials of MI Types According to
of the Applied Cardiac Biomarker
Multiples  99%
Ml type 1
Spontaneous
Ml type 2
Secondary
Ml type 3*
Death
1–3
3–5
5–10
10
Total
MI  myocardial infarction; PCI  percutaneous coronary intervention; CABG  coronary artery
*Biomarker values are unavailable because of death before blood samples are obtained (blu
Red areas indicate arbitrarily defined cTn values below the MI decision limit whether PCI or CA†Restenosis is defined as 50% stenosis at coronary angiography or a complex lesion associated wit
f greater severity following: (i) initially successful stent deployment or (ii) dilatation of a coronary arteI and includes the 99th percentile URL decision limits of
Tn or other biomarkers employed. Multiples of the 99th
ercentiles URL may be indicated as shown in Table 6. This
ill facilitate comparison of trials and meta-analyses.
Because different assays may be used, including newer,
igher-sensitivity cTn assays in large multicenter clinical
rials, it is advisable to consistently apply the 99th percentile
RL. This will not totally harmonize troponin values across
ifferent assays, but will improve the consistency of the
esults. In patients undergoing cardiac procedures, the
ncidence of MI may be used as a measure of quality,
rovided that a consistent definition is applied by all centers
articipating in the quality assurance program. To be
ffective and to avoid bias, this type of assessment will need
o develop a paradigm to harmonize the different cTn assay
esults across sites.
Public policy implications
of the adjustment of the MI definition
Revision of the definition of MI has a number of implica-
tions for individuals as well as for society at large. A
tentative or final diagnosis is the basis for advice about
further diagnostic testing, lifestyle changes, treatment and
prognosis for the patient. The aggregate of patients with a
particular diagnosis is the basis for health care planning and
policy and resource allocation.
One of the goals of good clinical practice is to reach a
definitive and specific diagnosis, which is supported by
current scientific knowledge. The approach to the definition
of MI outlined in this document meets this goal. In general,
the conceptual meaning of the term ‘myocardial infarction’
has not changed, although new, sensitive diagnostic meth-
ods have been developed to diagnose this entity. Thus, the
diagnosis of acute MI is a clinical diagnosis based on patient
symptoms, ECG changes, and highly sensitive biochemical
markers, as well as information gleaned from various imag-
ing techniques. It is important to characterize the type of
MI as well as the extent of the infarct, residual LV function,
and the severity of CAD and other risk factors, rather than
merely making a diagnosis of MI. The information con-
iples of the 99th Percentile Upper Reference Limit
Ml type 4a
PCI
Ml type 4b
Stent-Thrombus
Ml type 4c†
Restenosis
Ml type 5
CABG
grafting.
.Mult
bypass
e area)
BG.h a rise and/or fall of cTn values 99th percentile URL and no other significant obstructive CAD
ry stenosis with balloon angioplasty (50%).
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requires more than just the mere statement that the patient
has suffered an MI. The many additional factors just
mentioned are also required so that appropriate social,
family, and employment decisions can be made. A number
of risk scores have been developed to predict the prognosis
after MI. The classification of the various other prognostic
entities associated with MI should lead to a reconsideration
of the clinical coding entities currently employed for pa-
tients with the myriad conditions that can lead to myocar-
dial necrosis, with consequent elevation of biomarker values.
It should be appreciated that the current modification of
the definition of MI may be associated with consequences
for the patients and their families in respect of psychological
status, life insurance, professional career, as well as driving-
and pilots’ licenses. The diagnosis is associated also with
societal implications as to diagnosis-related coding, hospital
reimbursement, public health statistics, sick leave, and
disability attestation. In order to meet this challenge,
physicians must be adequately informed of the altered
diagnostic criteria. Educational materials will need to be
created and treatment guidelines must be appropriately
adapted. Professional societies and healthcare planners
should take steps to facilitate the rapid dissemination of the
revised definition to physicians, other health care profes-
sionals, administrators, and the general public.
Global perspectives of the
definition of myocardial infarction
Cardiovascular disease is a global health problem. Under-
standing the burden and effects of CAD in populations is of
critical importance. Changing clinical definitions, criteria
and biomarkers add challenges to our understanding and
ability to improve the health of the public. The definition of
MI for clinicians has important and immediate therapeutic
implications. For epidemiologists, the data are usually ret-
rospective, so consistent case definitions are critical for
comparisons and trend analysis. The standards described in
this report are suitable for epidemiology studies. However,
to analyze trends over time, it is important to have consis-
tent definitions and to quantify adjustments when biomark-
ers or other diagnostic criteria change (101). For example,
the advent of cTn dramatically increased the number of
diagnosable MIs for epidemiologists (3,102).
In countries with limited economic resources, cardiac
biomarkers and imaging techniques may not be available
except in a few centers, and even the option of ECG
recordings may be lacking. In these surroundings, the
WHO states that biomarker tests or other high-cost diag-
nostic testing are unfit for use as compulsory diagnostic
criteria (3). The WHO recommends the use of the ESC/
ACCF/AHA/WHF Universal MI Definition in settings
without resource constraints, but recommends more flexible
standards in resource-constrained locations (3).Cultural, financial, structural and organizational prob-
lems in the different countries of the world in the diagnosis
and therapy of acute MI will require ongoing investigation.
It is essential that the gap between therapeutic and diag-
nostic advances be addressed in this expanding area of
cardiovascular disease.
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